Amygdalar subnuclei are particularly affected in MAPT/FTDP-17, Pick’s disease and TDP-43 type C-associated frontotemporal dementia

Martina Bocchetta1, Juan Eugenio Iglesias2, David M. Cash1,2, Sebastien Ourselin3, Jason D. Warren1, Jonathan D. Rohrer1

1Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom
2Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom
3School of Biomedical Engineering and Imaging Sciences, St Thomas’ Hospital, King’s College London, London, United Kingdom

Background

Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder, with frontal and temporal atrophy. Subcortical involvement has been described too, but no study has so far focused on the amygdalar subnuclei (AS). The amygdala is composed of different subnuclei with mainly connections to the limbic system. It is involved in different aspects of reward learning, motivation, emotion, and in several cognitive functions (Figure 1).

Methods

We investigated AS involvement in a cohort of 132 patients with a genetic or pathologically confirmed diagnosis of FTD (age: mean (standard deviation) 61(8) years; disease duration: 5(3) years) compared with 107 age-matched controls (age: 63(11) years). We assessed subgroups stratified by genetic diagnosis (27 MAPT, 29 C9orf72, 18 GRN) and pathological confirmation: FUS (n=3), TDP-43 type A (n=16), TDP-43 type B (n=3), TDP-43 type C (n=20); tau with Pick’s disease (n=17), with PSP (n=6), with CBD (n=9), and due to FTDP-17 (n=7).

We performed an automated segmentation of T1-weighted MRIs to extract AS volumes (lateral, basal/paralaminar, accessory basal, superficial nuclei, cortico-amygdaloid transition area), using a customised version of the module available in FreeSurfer 6.0 (Saygin et al., 2017), to adapt the output of GIF (geodesic information flow) algorithm (Cardoso et al., 2015) to the FreeSurfer format.

Based on the volumes of the left and right hemispheres, we defined the most severely affected cerebral hemisphere in each patient, and we analyzed the AS volumes accordingly. We performed a linear regression analysis adjusted for age, gender, total intracranial volume, and scanner type.

We also investigated asymmetry by calculating an Asymmetry Index, defined as the absolute difference between the left and right total amygdalar volumes in relation to the total bilateral volume: |Left - Right|/(|Left + Right|).

Results

Overall, FTD patients had smaller AS than controls (29-34% difference for the most affected hemisphere, 23-26% for the least affected, p<0.0005).

MAPT group had the smallest AS in both hemispheres (37-43%, p<0.0005), while C9orf72 and GRN showed the most involvement in the superficial group and accessory basal subnucleus (24-29%, p<0.0005).

Stratifying by pathology, FTDP-17, TDP-43 type C and Pick’s disease were the most impaired groups, especially for the superficial (39-47%), accessory basal (38-50%), and basal/paralaminar subnuclei (35-39%, p<0.0005) in the most affected hemisphere (Figure 2). FUS showed a very homogenous involvement across all AS (28-31% for the most affected, 26-28% for the least affected hemisphere, p<0.003).

For most groups, no differences were seen between the right and left amygdalae, except for the GRN, Pick’s disease, CBD, and TDP-43 type C groups which had an asymmetry index significantly greater than controls (p<0.003).

Conclusions

The AS were most affected in MAPT/FTDP-17, Pick’s disease and TDP-43 type C. The most affected subnuclei were the superficial group, accessory basal, and basal/paralaminar which are part of the reward system and involved in emotion regulation.

Acknowledgements: The Dementia Research Centre is supported by Alzheimer’s Research UK, Brain Research Trust, and the Wolfson Foundation. NIHR Queen Square Dementia Biomedical Research Unit and the NIHR UCL/H Biomedical Research Centre, the MRC UK GENFI grant and the Alzheimer’s Society. JDR is an MRC Clinician Scientist and has received funding from the NIHR Rare Diseases Translational Research Collaboration.